Related Experiment Video
Updated: Feb 9, 2026

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
Published on: November 11, 2014
Two novel VCP missense variants identified in Japanese patients with multisystem proteinopathy
Michio Inoue1,2, Aritoshi Iida3, Shinichiro Hayashi1
11Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, 187-8551 Japan.
Abstract:
VCP mutations were first associated with inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) but was later associated with amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease. Now, a new name, "multisystem proteinopathy (MSP)", is proposed for this condition. VCP encodes valosin-containing protein, which is involved in protein degradation in the ubiquitin proteasome system. We report here two MSP patients with two novel heterozygous missense variants in VCP: c.259G>T (p.Val87Phe) and c.376A>G (p.Ile126Val).
Insights
Valosin-containing protein (VCP) gene mutations cause multisystem proteinopathy (MSP). This study identifies two novel VCP variants in MSP patients, expanding the understanding of this complex genetic disorder.
Area of Science:
- Genetics
- Molecular Biology
- Neurology
Background:
- Valosin-containing protein (VCP) gene mutations are linked to inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis, and Charcot-Marie-Tooth disease.
- A new unifying term, multisystem proteinopathy (MSP), is proposed for these VCP-associated conditions.
- VCP protein plays a crucial role in the ubiquitin proteasome system, essential for protein degradation.
Related Concept Videos
Histone Variants at the Centromere
Identifying Statistically Significant Differences: The F-Test
Patient-centered Care
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Pharmacodynamics in Geriatric Patients: Effects of Age

